首页 > 市场调查报告书 > 製药

再生医学细胞疗法

市场调查报告书

商品编码

1671847

自体细胞治疗市场：按产品类型、按应用、按技术、按最终用户、按地区

Autologous Cell Therapy Market, By Product Type, By Application, By Technology, By End User, By Geography

出版日期: 2025年01月07日 | 出版商:

Coherent Market Insights | 英文 155 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2025 年全球自体细胞治疗市场规模估计为 55.1 亿美元，预计到 2032 年将达到 223 亿美元，2025 年至 2032 年的复合年增长率为 22.1%。

报告范围		报告详细信息
基准年	2024	2025 年市场规模	55.1亿美元
效能资料	从 2020 年到 2024 年	预测期	2025 至 2032 年
预测期：2025-2032年复合年增长率：	22.10％	2032 年价值预测	223亿美元

数字。 2025 年自体细胞治疗市场占有率（%）（按地区）

近年来，全球自体细胞治疗市场经历了显着成长。自体细胞疗法包括从患者自身体内提取干细胞或其他类型的细胞，透过各种过程进行修改或扩增，然后将其註射回同一患者体内以治疗疾病。它提供了一种治疗癌症和神经系统疾病等复杂疾病的替代治疗方法，同时最大限度地减少免疫抗原性问题。慢性病盛行率的上升、个人化医疗的需求不断增长以及自体细胞相对于同种异体细胞的优势是预计未来推动自体细胞治疗需求的主要因素。然而，与市场开发和製造相关的高成本和监管挑战对市场构成了重大障碍。

市场动态：

全球自体细胞治疗市场受到以下因素的推动：老年人口不断增加，更容易患上慢性病；公共和私营公司对产品开发的投资不断增加；以及对个人化治疗方案的需求不断增长。然而，预计高昂的开发成本、复杂的製造流程以及严格的监管政策将在预测期内抑制市场成长。目前正在进行各种临床试验，以评估自体细胞疗法针对新适应症的有效性和安全性，创新製造技术的开发为现有企业和新参与企业创造了庞大的商机。主要企业正在与学术研究机构合作，扩大这些治疗方法的应用。由于中国和印度等主要国家的医疗保健基础设施不断增强以及医疗保健支出不断增加，亚太地区提供了有利可图的市场机会。

本研究的主要特点

本报告对全球自体细胞治疗市场进行了详细分析，并以 2024 年为基准年，展示了预测期（2025-2032 年）的市场规模和復合年增长率。

它还强调了各个领域的潜在商机并说明了该市场的有吸引力的投资提案矩阵。

它还提供了关于市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景和主要企业采用的竞争策略的主要考察。

全球自体细胞治疗市场的主要企业根据公司亮点、产品系列、关键亮点、财务绩效和策略等参数进行分析。

主要公司包括百时美施贵宝、诺华、吉利德科学、Kite Pharma、新基、安进、工业、默克、Bluebird Bio、Celyad Oncology、Adaptimmune Therapeutics、Allogene Therapeutics、Athersys, Inc.、BrainStorm Cell Therapeutics 和 Soentos Therapeutics。

本报告的见解将使负责人和企业经营团队能够就未来产品发布、新兴趋势、市场扩张和行销策略做出明智的决策。

本研究报告针对该产业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和财务分析师。

相关人员将透过用于分析全球自体细胞治疗市场的各种策略矩阵更轻鬆地做出决策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 5.51 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	22.10%	2032 Value Projection:	USD 22.30 Bn

The global autologous cell therapy market has been witnessing significant growth in the recent years. Autologous cell therapy involves the collection of stem cells or other types of cells from patient's own body, modifying or expanding them through various processes and infusing back to the same patient to treat diseases. It provides an alternative therapeutic approach to treat complex diseases like cancer and neurological disorders with minimal immunogenicity concerns. Rising prevalence of chronic diseases, growing demand for personalized medicine, and advantages of autologous cells over allogeneic cells are some key factors expected to propel demand for autologous cell therapies going forward. However, high costs associated with development and manufacturing along with regulatory challenges are major barriers to the market.

Market Dynamics:

The global autologous cell therapy market is driven by rising geriatric population vulnerable to develop chronic diseases, increasing investments from public and private players to expedite product development, and growing demand for personalized treatment options. However, high development costs, complex manufacturing processes, and stringent regulatory policies are projected to restrain the market growth during the forecast period. Various ongoing clinical trials evaluating efficacy and safety of autologous cell therapies for new indications and development of innovative manufacturing technologies present significant opportunities for existing as well as new market players. Key players are collaborating with academic research institutions to expand applications of these therapies. Asia Pacific presents lucrative market opportunities with growing healthcare infrastructure and increasing healthcare spending in major countries like China and India.

Key Features of the Study:

This report provides in-depth analysis of the global autologous cell therapy market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global autologous cell therapy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Bristol Myers Squibb, Novartis, Gilead Sciences, Kite Pharma, Celgene, Amgen, Takeda Pharmaceutical Company, Merck KGaA, Bluebird Bio, Celyad Oncology, Adaptimmune Therapeutics, Allogene Therapeutics, Athersys, Inc., BrainStorm Cell Therapeutics, and Sorrento Therapeutics

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global autologous cell therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global autologous cell therapy market

Market Segmentation

Product Type Insights (Revenue, USD Bn, 2020 - 2032)
- Cell-based therapies
- Tissue-based therapies
- Gene therapies
Application Insights (Revenue, USD Bn, 2020 - 2032)
- Oncology
- Cardiovascular diseases
- Neurological disorders
- Orthopedic disorders
- Autoimmune diseases
- Wound healing
Technology Insights (Revenue, USD Bn, 2020 - 2032)
- Stem cell therapy
- CAR T-cell therapy
- T-cell receptor (TCR) therapy
- Induced pluripotent stem cells (iPSCs)
End User Insights (Revenue, USD Bn, 2020 - 2032)
- Hospitals
- Research institutes
- Biotechnology companies
- Pharmaceutical companies
- Others
Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Bristol Myers Squibb
- Novartis
- Gilead Sciences
- Kite Pharma
- Celgene
- Amgen
- Takeda Pharmaceutical Company
- Merck KGaA
- Bluebird Bio
- Celyad Oncology
- Adaptimmune Therapeutics
- Allogene Therapeutics
- Athersys, Inc.
- BrainStorm Cell Therapeutics
- Sorrento Therapeutics

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Autologous Cell Therapy Market, By Product Type
- Global Autologous Cell Therapy Market, By Application
- Global Autologous Cell Therapy Market, By Technology
- Global Autologous Cell Therapy Market, By End User
- Global Autologous Cell Therapy Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Driver
Restraint
Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Autologous Cell Therapy Market, By Product Type, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Cell-based therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Tissue-based therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Gene therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Autologous Cell Therapy Market, By Application, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Oncology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Cardiovascular diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Neurological disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Orthopedic disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Autoimmune diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Wound healing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Autologous Cell Therapy Market, By Technology, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Stem cell therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
CAR T-cell therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
T-cell receptor (TCR) therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Induced pluripotent stem cells (iPSCs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Autologous Cell Therapy Market, By End User, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Research institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Biotechnology companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Pharmaceutical companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Autologous Cell Therapy Market, By Region, 2020 - 2032, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

9. Competitive Landscape

Bristol Myers Squibb
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Gilead Sciences
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Kite Pharma
Celgene
Amgen
Takeda Pharmaceutical Company
Merck KGaA
Bluebird Bio
Celyad Oncology
Adaptimmune Therapeutics
Allogene Therapeutics
Athersys, Inc.
BrainStorm Cell Therapeutics
Sorrento Therapeutics

10. Analyst Recommendations

Wheel of Fortune
Analyst View
Coherent Opportunity Map

11. References and Research Methodology

References
Research Methodology
About us

02-2729-4219

+886-2-2729-4219

License/价格

自体细胞治疗市场：按产品类型、按应用、按技术、按最终用户、按地区